Clinical Trial Update: Stress Echocardiography Study With Regadenoson [Phase 2]

View source ↗

Summary

Phase 2 stress echocardiography study with regadenoson sponsored by Gilead Sciences has been terminated. Status: TERMINATED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Heart Disease

Drugs mentioned

• Regadenoson (Regadenoson)

Snippet

Sponsor: Gilead Sciences | Conditions: Heart Disease, Coronary Artery Disease | Phase 2 | Status: TERMINATED